---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000645"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-05-19T11:00:48+00:00"
generated_at: "2026-05-19T11:05:58.604313+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts

## Summary
- Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
- Bonney brings 30+ years biopharma experience, including Avonex launch at Biogen and CEO of Cubist (acquired by Merck for $9.5B).
- Board size increased from 9 to 10; Bonney received option grant for 100k shares vesting over 3 years.
- Company advances vidofludimus calcium toward phase 3 ENSURE readout in relapsing MS and planned PPMS program.
- Simona Skerjanec remains as board member after transitioning from Interim Chair.

## SEC filing metadata
- accession: 0001193805-26-000645
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-05-19T11:00:48+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/e665479_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000645
- JSON: https://secwatch.observer/filing/0001193805-26-000645.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000645.txt

## Key facts
- Executive change
  Simona Skerjanec changed role as Member of the Board at IMMUNIC, INC..
  - Action: transitioned from Interim Chairperson
  - Role: Member of the Board
  source text: Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm
- Executive change
  Michael W. Bonney was appointed as Chair of the Board at IMMUNIC, INC..
  - Action: appointed
  - Role: Chair of the Board
  source text: appointed Michael W. Bonney as Chair of the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000645/0001193805-26-000645-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.